FDA Approved: RUBRACA — Supplemental Application (pharmaand GmbH)

View source ↗

Summary

FDA approved a supplemental application for RUBRACA (rucaparib) submitted by pharmaand GmbH, expanding the labeling for ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• RUBRACA (RUCAPARIB)

Snippet

SUPPL AP for RUBRACA (RUCAPARIB)